A Phase 3 interventional study of trastuzumab (Herceptin®) and anastrazole (Arimidex®) in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 132 sites in 26 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-13.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 76th largest by enrollment of the 366 interventional ones that give a count, is one of 13 that started in 2001, is one of 60 in phase 3, and was the 24th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 13 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 27 under way, 13 of them phase 3. Of 194 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 67th largest by enrollment of the 170 interventional ones that give a count, is one of 4 that started in 2001, is one of 61 in phase 3, and was the 3rd registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.
Drug: trastuzumab (Herceptin®) · Drug: anastrazole (Arimidex®)
1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.
Drug: anastrazole (Arimidex®)
4mg/kg iv loading dose, followed by 2mg/kg iv weekly
Also known as: Herceptin®
1 mg tablet taken orally daily
Also known as: Arimidex®
Progression Free Survival (PFS)
PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations. Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion. For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm\^2) an increase of 1.0 cm\^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required. PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death. Kaplan Meier estimates of PFS are presented.
Time frame: 24 Months, End of Study (Up to 5 years)
Percentage of Participants With Clinical Benefit
Clinical Benefit was defined as stable disease for ≥ six months or complete response or partial response.
Time frame: 24 Months, End of Study (Up to 5 years)
Duration of Response at 24 Months
Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.
Time frame: 24 Months
Time to Response at 24 Months
Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.
Time frame: 24 Months
Overall Survival at 24 Months
Overall Survival is defined as the number of days from randomization to death.
Time frame: 24 Months
Percentage of Participants With Two-Year Survival
Time frame: 24 Months
Percentage of Participants With Overall Tumor Response at 24 Months
Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.
Time frame: 24 Months
Percentage of Participants With Best Tumor Response at 24 Months
Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.
Time frame: 24 Months
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Final Visit Compared to Baseline
Participants rated their performance status using the ECOG Questionnaire on the following scale: 0=Fully active, perform all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature; 2=Ambulatory, capable of self-care, unable to carry out any work activities, up and about more than \>50% of waking hours; 3=Capable of limited self-care, confined to bed or chair \>50% of waking hours; 4=Completely disabled, not capable of any self-care, totally confined to bed or chair; 5=Dead. The percentage of participants in the following categories: Improved: Score decrease from baseline. Unchanged: Score the same as baseline. Worse: Score increase from baseline.
Time frame: Baseline, Final Visit (Up to 24 Months)
Duration of Response at End of Study
Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.
Time frame: End of Study (Up to 5 years)
Time to Response at End of Study
Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.
Time frame: End of Study (Up to 5 years)
Percentage of Participants With Overall Tumor Response at End of Study
Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.
Time frame: End of Study (Up to 5 years)
Percentage of Participants With Best Tumor Response at End of Study
Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.
Time frame: End of Study (Up to 5 years)
Number of Participants With Adverse Events
Number of participants with adverse events as a measure for safety as assessed by the collection of adverse events, laboratory tests for Hematology and Serum Chemistry, clinical assessments and cardiac monitoring.
Time frame: Throughout the Study (Up to 5 years)
| Milestone | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Started | 103 | 104 |
| Safety set: received study drug | 103 | 104 |
| Completed | 16 | 4 |
| Not completed | 87 | 100 |
| Withdrew: Adverse event | 6 | 0 |
| Withdrew: Death | 0 | 3 |
| Withdrew: Insufficient therapeutic response | 75 | 91 |
| Withdrew: Violation of selection criteria at entry | 0 | 1 |
| Withdrew: Other protocol violation | 1 | 0 |
| Withdrew: Refused treatment | 3 | 4 |
| Withdrew: Failure to return | 1 | 1 |
| Withdrew: Other | 1 | 0 |
| Milestone | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Started | 14 | 58 |
| Safety set: received study drug | 14 | 58 |
| Completed | 11 | 7 |
| Not completed | 3 | 51 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Insufficient therapeutic response | 1 | 44 |
| Withdrew: Refused treatment | 0 | 2 |
| Withdrew: Other | 1 | 1 |
PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations. Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion. For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm\^2) an increase of 1.0 cm\^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required. PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death. Kaplan Meier estimates of PFS are presented.
| Months | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| 24 Months | 4.8 (3.7 to 7) | 2.4 (2 to 4.6) |
| End of Study | 5.8 (4.6 to 8.3) | 2.9 (2.1 to 4.5) |
Clinical Benefit was defined as stable disease for ≥ six months or complete response or partial response.
| Percentage of participants | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| 24 Months | 42.7 | 27.9 |
| End of Study | 45.6 | 30.8 |
Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.
| Months | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Duration of Response at 24 Months | 9.5 (3.8 to 50.6) | 10.0 (5.3 to 33.1) |
Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.
| Months | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Time to Response at 24 Months | 2.0 (1.4 to 12.1) | 2.0 (1.7 to 4.1) |
Overall Survival is defined as the number of days from randomization to death.
| Months | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Overall Survival at 24 Months | 28.5 (22.8 to 42.4) | 23.9 (18.2 to 37.4) |
| Percentage of participants | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Percentage of Participants With Two-Year Survival | 52.4 | 45.2 |
Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.
| Percentage of participants | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Percentage of Participants With Overall Tumor Response at 24 Months | 20.3 | 6.8 |
Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.
| Percentage of participants | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Complete Response | 0.0 | 0.0 |
| Partial Response | 20.3 | 6.8 |
| Stable Disease | 37.8 | 38.4 |
| Progressive Disease | 40.5 | 49.3 |
| Response not assessed | 1.4 | 5.5 |
Participants rated their performance status using the ECOG Questionnaire on the following scale: 0=Fully active, perform all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature; 2=Ambulatory, capable of self-care, unable to carry out any work activities, up and about more than \>50% of waking hours; 3=Capable of limited self-care, confined to bed or chair \>50% of waking hours; 4=Completely disabled, not capable of any self-care, totally confined to bed or chair; 5=Dead. The percentage of participants in the following categories: Improved: Score decrease from baseline. Unchanged: Score the same as baseline. Worse: Score increase from baseline.
| Percentage of participants | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Improved | 10.3 | 4.1 |
| No Change | 67.6 | 64.4 |
| Worse | 22.1 | 31.5 |
Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.
| Months | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Duration of Response at End of Study | 12.3 (3 to 59.1) | 8.2 (2.6 to 60.5) |
Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.
| Months | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Time to Response at End of Study | 2.4 (1.7 to 12.1) | 2.1 (1.3 to 5.1) |
Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.
| Percentage of participants | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Percentage of Participants With Overall Tumor Response at End of Study | 22.3 | 8.7 |
Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.
| Percentage of participants | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Complete Response | 1.0 | 3.8 |
| Partial Response | 21.4 | 4.8 |
| Stable Disease | 47.6 | 40.4 |
| Progressive Disease | 28.1 | 46.2 |
| Response not assessed | 1.9 | 4.8 |
Number of participants with adverse events as a measure for safety as assessed by the collection of adverse events, laboratory tests for Hematology and Serum Chemistry, clinical assessments and cardiac monitoring.
| Participants | Trastuzumab + Anastrozole | Anastrozole |
|---|---|---|
| Number of Participants With Adverse Events | 90 | 68 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab + Anastrozole | — | 25/103 (24.3%) | 89/103 (86.4%) |
| Anastrozole | — | 6/104 (5.8%) | 68/104 (65.4%) |
| Anastrozole (After Start of Trastuzumab) | — | 8/58 (13.8%) | 40/58 (69%) |
| Event | Trastuzumab + Anastrozole | Anastrozole | Anastrozole (After Start of Trastuzumab) |
|---|---|---|---|
| VomitingGastrointestinal disorders | 3/103 | 0/104 | 0/58 |
| Chest painGeneral disorders | 3/103 | 0/104 | 0/58 |
| NauseaGastrointestinal disorders | 2/103 | 0/104 | 0/58 |
| PainGeneral disorders | 2/103 | 0/104 | 0/58 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/103 | 0/104 | 0/58 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 1/103 | 0/104 | 1/58 |
| HypertensionVascular disorders | 1/103 | 0/104 | 1/58 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/103 | 1/104 | 1/58 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/103 | 0/104 | 1/58 |
| DyspepsiaGastrointestinal disorders | 0/103 | 0/104 | 1/58 |
| Event | Trastuzumab + Anastrozole | Anastrozole | Anastrozole (After Start of Trastuzumab) |
|---|---|---|---|
| FatigueGeneral disorders | 22/103 | 10/104 | 4/58 |
| VomitingGastrointestinal disorders | 21/103 | 5/104 | 5/58 |
| DiarrhoeaGastrointestinal disorders | 20/103 | 8/104 | 8/58 |
| PyrexiaGeneral disorders | 17/103 | 6/104 | 4/58 |
| NasopharyngitisInfections and infestations | 17/103 | 2/104 | 2/58 |
| NauseaGastrointestinal disorders | 15/103 | 5/104 | 5/58 |
| ChillsGeneral disorders | 15/103 | 0/104 | 3/58 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/103 | 9/104 | 3/58 |
| Back painMusculoskeletal and connective tissue disorders | 15/103 | 7/104 | 3/58 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/103 | 6/104 | 4/58 |
| Age Continuous(years) | Trastuzumab + Anastrozole | Anastrozole | Total |
|---|---|---|---|
| Mean | 57.4 ± 10.6 | 55.5 ± 10.7 | 56.5 ± 10.7 |
| Sex: Female, Male(Participants) | Trastuzumab + Anastrozole | Anastrozole | Total |
|---|---|---|---|
| Female | 103 | 104 | 207 |
| Male | 0 | 0 | 0 |
Showing the first 100 of 132 sites across 26 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2001, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab